快速的埃诺沙巴林调整儿童血栓形成/血栓预防
Joel Livingston1,2,3, Leanne Meakins1,2, Aisha Bruce1,2
1Department of Pediatrics, The University of Alberta, Edmonton, Alberta, Canada.
Pediatric blood & cancer
|April 5, 2025
概括
在高风险儿科患者中使用抗Xa水平达到峰值的优化埃诺沙林剂量可以快速实现治疗目标. 这项回顾性研究没有发现任何不良事件,这表明小儿血栓瘤管理的有希望的方法.
科学领域:
- 儿科血栓形成症 儿童血栓形成症
- 药理动力学 药理动力学
- 抗凝固疗法 抗凝固疗法
背景情况:
- 在儿童中使用埃诺沙的剂量具有挑战性,因此对于高血栓风险患者需要优化策略.
- 目前的剂量方案可能无法始终迅速达到治疗性抗凝血水平.
研究的目的:
- 评价峰抗因子Xa (抗Xa) 水平在初始注射后的效用,以指导后续注射,在患有高血栓形成风险的儿科患者.
- 评估达到治疗性抗Xa水平的时间和不良事件的发生率.
主要方法:
- 对14名儿童患者 (7名新生儿/婴儿<3个月,7名儿童/青少年) 接受治疗性埃诺沙的回顾性评估.
- 埃诺沙巴林剂量根据抗Xa水平的峰值进行调整.
- 记录了治疗性抗Xa水平的时间和临床结果 (血栓,出血).
主要成果:
- 所有患者在20小时内都获得了治疗性埃诺沙巴林剂量.
- 新生儿/婴儿治疗性抗Xa水平的平均时间为15.4小时,儿童/青少年为10.8小时.
- 没有患者经历过超治疗性抗Xa水平,血栓事件或出血并发症.
结论:
- 使用高峰抗Xa水平来指导高风险儿科患者的埃诺沙巴林剂量似乎是安全有效的,以实现治疗目标.
- 这种策略可以优化最初的抗凝治疗,减少治疗效果的时间.
- 需要进一步的前性研究来验证这些发现,并在临床实践中建立这种方法.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
570
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
570
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K
Factors Affecting Drug Response: Overview
1.7K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.7K
Renal Failure: Dose Adjustments
45
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
45
Drug Dosage Regimen: Overview
3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
52
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
52


